Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1965-1975

  Bock, Felix ^a   Rössner, Susanne ^b   Onderka, Jasmine ^b   Lechmann, Matthias ^b   Pallotta, Maria Teresa ^c   Fallarino, Francesca ^c   Boon, Louis ^d   Nicolette, Charles ^e   DeBenedette, Mark A ^e   Tcherepanova, Irina Y ^e   Grohmann, Ursula ^c   Steinkasserer, Alexander ^b   Cursiefen, Claus ^a   Zinser, Elisabeth ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF PERUGIA   (Italy)

^d BIOCEROS   (Netherlands)

^e Argos Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN; IDO PROTEIN; RECOMBINANT CD83 ANTIGEN; REGULATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; CORNEA TRANSPLANTATION; CYTOKINE PRODUCTION; FEMALE; FOXP3+ T LYMPHOCYTE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PARACRINE SIGNALING; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT RESPONSE;

ADMINISTRATION, OPHTHALMIC; ALLOGRAFTS; ANIMALS; ANTIGENS, CD; BONE MARROW CELLS; CELLS, CULTURED; COCULTURE TECHNIQUES; CORNEAL TRANSPLANTATION; DENDRITIC CELLS; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INJECTIONS, INTRAPERITONEAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PREMEDICATION; RECOMBINANT PROTEINS; SOLUBILITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION TOLERANCE;

EID: 84881464081     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201531     Document Type: Article

References (57)

1. Lechler, R. I., M. Sykes, A. W. Thomson, and L. A. Turka. 2005. Organ transplantation-how much of the promise has been realized? Nat. Med. 11: 605-613.
2. Williams, K. A., A. J. Esterman, C. Bartlett, H. Holland, N. B. Hornsby, and D. J. Coster. 2006. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation 81: 896-901.
3. Bachmann, B., R. S. Taylor, and C. Cursiefen. 2010. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidencebased meta-analysis. Ophthalmology 117: 1300-1305, e7.
4. Coster, D. J., and K. A. Williams. 2005. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am. J. Ophthalmol. 140: 1112-1122.
5. Chen, L., P. Hamrah, C. Cursiefen, Q. Zhang, B. Pytowski, J. W. Streilein, and M. R. Dana. 2004. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 10: 813-815.
6. Carnahan, M. C., and D. A. Goldstein. 2000. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr. Opin. Ophthalmol. 11: 478-483.
7. Hill, J. C. 1995. Immunosuppression in corneal transplantation. Eye (Lond.) 9: 247-253.
8. Javadi, M. A., S. Feizi, A. Karbasian, and A. Rastegarpour. 2010. Efficacy of topical ciclosporin A for treatment and prevention of graft rejection in corneal grafts with previous rejection episodes. Br. J. Ophthalmol. 94: 1464-1467.
9. Sinha, R., V. Jhanji, K. Verma, N. Sharma, N. R. Biswas, and R. B. Vajpayee. 2010. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch. Clin. Exp. Ophthalmol. 248: 1167-1172.
10. Hegde, S., C. Beauregard, E. Mayhew, and J. Y. Niederkorn. 2005. CD4(+) Tcell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. Transplantation 79: 23-31.
11. Torres, P. F., A. F. De Vos, R. van der Gaag, B. Martins, and A. Kijlstra. 1996. Cytokine mRNA expression during experimental corneal allograft rejection. Exp. Eye Res. 63: 453-461.
12. Kuffová, L., L. Lumsden, V. Veselá, J. A. Taylor, M. Filipec, V. Holán, A. D. Dick, and J. V. Forrester. 2001. Kinetics of leukocyte and myeloid cell traffic in the murine corneal allograft response. Transplantation 72: 1292-1298.
13. Bradley, B. A. 2002. Rejection and recipient age. Transpl. Immunol. 10: 125-132.
14. Forrester, J. V., H. Xu, L. Kuffová, A. D. Dick, and P. G. McMenamin. 2010. Dendritic cell physiology and function in the eye. Immunol. Rev. 234: 282-304.
15. Hamrah, P., Q. Zhang, Y. Liu, and M. R. Dana. 2002. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest. Ophthalmol. Vis. Sci. 43: 639-646.
16. Novak, N., K. Siepmann, M. Zierhut, and T. Bieber. 2003. The good, the bad and the ugly-APCs of the eye. Trends Immunol. 24: 570-574.
17. Yamagami, S., and S. Amano. 2003. Role of resident corneal leukocytes and draining cervical lymph nodes in corneal allograft rejection. Cornea 22(Suppl. 7): S61-S65.
18. Maruyama, K., M. Ii, C. Cursiefen, D. G. Jackson, H. Keino, M. Tomita, N. Van Rooijen, H. Takenaka, P. A. D'Amore, J. Stein-Streilein, et al. 2005. Inflammation-induced lymphangiogenesis in the cornea arises from CD11bpositive macrophages. J. Clin. Invest. 115: 2363-2372.
19. Dilioglou, S., J. M. Cruse, and R. E. Lewis. 2003. Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells. Exp. Mol. Pathol. 75: 217-227.
20. Pardoll, D. M. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2: 227-238.
21. Twist, C. J., D. R. Beier, C. M. Disteche, S. Edelhoff, and T. F. Tedder. 1998. The mouse Cd83 gene: structure, domain organization, and chromosome localization. Immunogenetics 48: 383-393.
22. Berchtold, S., P. Mühl-Zürbes, C. Heufler, P. Winklehner, G. Schuler, and A. Steinkasserer. 1999. Cloning, recombinant expression and biochemical characterization of the murine CD83 molecule which is specifically upregulated during dendritic cell maturation. FEBS Lett. 461: 211-216.
23. Aerts-Toegaert, C., C. Heirman, S. Tuyaerts, J. Corthals, J. L. Aerts, A. Bonehill, K. Thielemans, and K. Breckpot. 2007. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 37: 686-695.
24. Prechtel, A. T., N. M. Turza, A. A. Theodoridis, and A. Steinkasserer. 2007. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J. Immunol. 178: 5454-5464.
25. Hock, B. D., M. Kato, J. L. McKenzie, and D. N. Hart. 2001. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int. Immunol. 13: 959-967.
26. Hock, B. D., L. F. Haring, A. Steinkasserer, K. G. Taylor, W. N. Patton, and J. L. McKenzie. 2004. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk. Res. 28: 237-241.
27. Hock, B. D., L. J. Fernyhough, S. M. Gough, A. Steinkasserer, A. G. Cox, and J. L. McKenzie. 2009. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk. Res. 33: 1089-1095.
28. Lechmann, M., D. J. Krooshoop, D. Dudziak, E. Kremmer, C. Kuhnt, C. G. Figdor, G. Schuler, and A. Steinkasserer. 2001. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J. Exp. Med. 194: 1813-1821.
29. Lan, Z., D. Lian, W. Liu, J. Arp, B. Charlton, W. Ge, S. Brand, D. Healey, M. DeBenedette, C. Nicolette, et al. 2010. Prevention of chronic renal allograft rejection by soluble CD83. Transplantation 90: 1278-1285.
30. Scholler, N., M. Hayden-Ledbetter, A. Dahlin, I. Hellström, K. E. Hellström, and J. A. Ledbetter. 2002. Cutting edge: CD83 regulates the development of cellular immunity. J. Immunol. 168: 2599-2602.
31. Breloer, M., B. Kretschmer, K. Lüthje, S. Ehrlich, U. Ritter, T. Bickert, C. Steeg, S. Fillatreau, K. Hoehlig, V. Lampropoulou, and B. Fleischer. 2007. CD83 is a regulator of murine B cell function in vivo. Eur. J. Immunol. 37: 634-648.
32. Kretschmer, B., K. Lüthje, S. Schneider, B. Fleischer, and M. Breloer. 2009. Engagement of CD83 on B cells modulates B cell function in vivo. J. Immunol. 182: 2827-2834.
33. Zinser, E., M. Lechmann, A. Golka, M. B. Lutz, and A. Steinkasserer. 2004. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J. Exp. Med. 200: 345-351.
34. Xu, J. F., B. J. Huang, H. Yin, P. Xiong, W. Feng, Y. Xu, M. Fang, F. Zheng, C. Y. Wang, and F. L. Gong. 2007. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transpl. Int. 20: 266-276.
35. Ge, W., J. Arp, D. Lian, W. Liu, M. L. Baroja, J. Jiang, S. Ramcharran, F. Z. Eldeen, E. Zinser, A. Steinkasserer, et al. 2010. Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection. Transplantation 90: 1145-1156.
36. Dietrich, T., F. Bock, D. Yuen, D. Hos, B. O. Bachmann, G. Zahn, S. Wiegand, L. Chen, and C. Cursiefen. 2010. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J. Immunol. 184: 535-539.
37. Cursiefen, C., J. Cao, L. Chen, Y. Liu, K. Maruyama, D. Jackson, F. E. Kruse, S. J. Wiegand, M. R. Dana, and J. W. Streilein. 2004. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 45: 2666-2673.
38. Lechmann, M., E. Kremmer, H. Sticht, and A. Steinkasserer. 2002. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies. Protein Expr. Purif. 24: 445-452.
39. Xu, Y., L. Zhang, W. Yao, S. S. Yedahalli, S. Brand, M. Moo-Young, and C. Perry Chou. 2009. Bioprocess development for production, purification, and structural characterization of recombinant hCD83ext as a potential therapeutic protein. Protein Expr. Purif. 65: 92-99.
40. Wang, F., Y. Sun, Y. Lu, and W. Ma. 2008. [Effect of TGF-beta1 on expression of integrin beta1 following corneal alkali burns in rabbits]. Yan Ke Xue Bao 24: 13-17.
41. Fallarino, F., C. Volpi, F. Fazio, S. Notartomaso, C. Vacca, C. Busceti, S. Bicciato, G. Battaglia, V. Bruno, P. Puccetti, et al. 2010. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat. Med. 16: 897-902.
42. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rössner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77-92.
43. Zal, T., A. Volkmann, and B. Stockinger. 1994. Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J. Exp. Med. 180: 2089-2099.
44. Pallotta, M. T., C. Orabona, C. Volpi, C. Vacca, M. L. Belladonna, R. Bianchi, G. Servillo, C. Brunacci, M. Calvitti, S. Bicciato, et al. 2011. Indoleamine 2,3- dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12: 870-878.
45. Munn, D. H., M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall, C. Brown, and A. L. Mellor. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193.
46. Grohmann, U., F. Fallarino, and P. Puccetti. 2003. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24: 242-248.
47. Puccetti, P., and U. Grohmann. 2007. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol. 7: 817-823.
48. Lan, Z., W. Ge, J. Arp, J. Jiang, W. Liu, D. Gordon, D. Healey, M. DeBenedette, C. Nicolette, B. Garcia, and H. Wang. 2010. Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indolamine 2,3-dioxygenase. Transplantation 90: 1286-1293.
49. Beutelspacher, S. C., R. Pillai, M. P. Watson, P. H. Tan, J. Tsang, M. O. McClure, A. J. George, and D. F. Larkin. 2006. Function of indolamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol. 36: 690-700.
50. Zaher, S. S., C. Germain, H. Fu, D. F. Larkin, and A. J. George. 2011. 3- hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatorycell development, and prolongs corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 52: 2640-2648.
51. Zaher, S. S., D. Coe, J. G. Chai, D. F. Larkin, and A. J. George. 2013. Suppression of the allogeneic response by the anti-allergy drug N-(3,4-dimethoxycinnamonyl) anthranilic acid results from T-cell cycle arrest. Immunology 138: 157-164.
52. Brereton, H. M., S. D. Taylor, A. Farrall, D. Hocking, M. A. Thiel, M. Tea, D. J. Coster, and K. A. Williams. 2005. Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br. J. Ophthalmol. 89: 1205-1209.
53. Hattori, T., D. R. Saban, P. Emami-Naeini, S. K. Chauhan, T. Funaki, H. Ueno, and R. Dana. 2012. Donor-derived, tolerogenic dendritic cells suppress immune rejection in the indirect allosensitization-dominant setting of corneal transplantation. J. Leukoc. Biol. 91: 621-627.
54. Chauhan, S. K., D. R. Saban, H. K. Lee, and R. Dana. 2009. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J. Immunol. 182: 148-153.
55. Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774.
56. Romani, L., F. Fallarino, A. De Luca, C. Montagnoli, C. D'Angelo, T. Zelante, C. Vacca, F. Bistoni, M. C. Fioretti, U. Grohmann, et al. 2008. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451: 211-215.
57. Belladonna, M. L., C. Orabona, U. Grohmann, and P. Puccetti. 2009. TGFbeta and kynurenines as the key to infectious tolerance. Trends Mol. Med. 15: 41-49.